WX-216
- Generic Name
- WX-216
Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06248567
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, China
Pharmacokinetics of ZSP1273 in Elder Participants
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT06157450
- Locations
- 🇨🇳
Sir Run Run Hospital, Nanjing, Jiangsu, China
Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid
Phase 1
Completed
- Conditions
- Drug Drug Interaction
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 49
- Registration Number
- NCT05954624
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou University of Chinese medicine, Guangzhou, China
A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 28
- Registration Number
- NCT05942365
- Locations
- 🇨🇳
the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT05856513
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, China
Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT05108051
- Locations
- 🇨🇳
Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China
The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: ZSP1273 High DoseDrug: ZSP1273 900 mgDrug: ZSP1273 100 mgDrug: ZSP1273 200 mgDrug: ZSP1273 400 mgDrug: ZSP1273 600 mgDrug: ZSP1273 1200 mgDrug: ZSP1273 Low DoseDrug: ZSP1273 Median DoseDrug: Placebo 1200 mgDrug: Placebo 600 mgDrug: PlaceboDrug: Placebo 200 mgDrug: Placebo 400 mgDrug: Placebo 900 mgDrug: Placebo 100 mg
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Target Recruit Count
- 103
- Registration Number
- NCT03679143
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath